Makreo Research and Consulting’s Post

As we celebrated #WorldPneumoniaDay yesterday, this article by Anita Shet and Rose Weeks https://lnkd.in/e8ieHz2y reminds us that many children are missing out on the lifesaving pneumococcal conjugate vaccines #PCVs. Anita and Rose discuss four reasons that contribute to this, #Conflict, #Climatechange, #VaccineMisinformation and #VaccineShortages Full blog article here: https://lnkd.in/dCeGFBdT Recognizing the high cost of PCVs (~ $2 to $3.30 per dose) , especially for low- and lower-middle income countries, we conducted a large non-inferiority trial of fractional doses of #PCV10 and #PCV13 between 2019 and 2021 in Kilifi, Kenya. With this trial, we sought to determine whether fractional doses of PCVs conferred immunity against pneumococcal pneumonia among infants. If so, smaller doses of the existing PCVs could be used in place of full doses thus reducing the cost of immunization per child and fill in gaps due to vaccine shortages. Our paper published in the NEJM Group in September this year, reported that 40% doses of #PCV13 are noninferior to full doses for all included serotypes in a three-dose schedule (two primary doses and a booster). What this means is that, the present 4-dose vials of #PCV13 could be reclassified as 10-dose vials of 40% doses (0.2 ml per dose) offering a more affordable option ($1.10 per dose) that reduces the cost of purchasing the vaccines. Funded by the Bill & Melinda Gates Foundation, our trial findings highlight the value of fractional doses of vaccines in reducing cost and increasing access to life-saving vaccines during shortages. Kate Gallagher Anthony Scott Christian Bottomley Dr. Mary Kaniu Suaad Badaud Mary Mutahi Laura Mwalekwa Sarah Ragab Louise Twi-Yeboah Jay Berkley Mainga Hamaluba Angela Karani Jimmy Shangala Mark Otiende Elizabeth Gardiner Daisy Mugo Collins Tabu Fred Were

The viral vaccines market is set to reach US$64.18 billion by 2031, driven by increasing government immunization initiatives and advancements in vaccine technology. Notably, the Asia-Pacific region is poised to lead growth due to higher healthcare expenditure and improved public awareness. This trend highlights the positive impact on global health by expanding vaccine accessibility and effectiveness. Stay updated with the latest trends shaping the health industry by following Mexico Business News. #health #vaccines #globalhealth #innovation #APAC #trends https://lnkd.in/gT5jFpKi

𝐏𝐧𝐞𝐮𝐦𝐨𝐧𝐢𝐚 𝐕𝐚𝐜𝐜𝐢𝐧𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭: 𝐑𝐢𝐬𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝 𝐃𝐫𝐢𝐯𝐞𝐧 𝐛𝐲 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞𝐬 𝐚𝐧𝐝 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐨𝐟 𝐑𝐞𝐬𝐩𝐢𝐫𝐚𝐭𝐨𝐫𝐲 𝐇𝐞𝐚𝐥𝐭𝐡 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/dQf4tZtC The pneumonia vaccine market is witnessing significant growth due to rising awareness about respiratory diseases, expanded immunization programs, and the increasing prevalence of bacterial pneumonia among vulnerable populations. Vaccines such as PCV (Pneumococcal Conjugate Vaccine) and PPSV (Pneumococcal Polysaccharide Vaccine) play a critical role in preventing pneumonia, especially in infants, the elderly, and immunocompromised individuals. The ongoing focus on public health and preventative care, coupled with government and private sector investments in vaccination, is expected to drive market growth further. Market Trends: Expansion of Global Immunization Programs: Initiatives by organizations like WHO and UNICEF to improve vaccine access in developing regions are driving demand for pneumonia vaccines, especially in areas with limited healthcare infrastructure. Rise in Adult Vaccination Awareness: Greater awareness of pneumonia risks among adults, particularly older adults, has led to an increase in demand for pneumococcal vaccines globally. Technological Advancements in Vaccine Development: Innovations in vaccine delivery methods and research into next-generation vaccines are enhancing the effectiveness of pneumonia immunization, supporting market growth. Government Support and Reimbursement Policies: Many countries are implementing policies to subsidize or reimburse vaccination costs, which is encouraging higher vaccination rates. Growth in the Pediatric Segment: Increased pediatric vaccinations, mandated in many healthcare systems, are propelling the market as part of a broader strategy to reduce childhood mortality rates. #Company Pfizer Glaxosmithkline Plc. Merck & Co., Inc. Sanofi Pasteur MSD Serum Institute of India Pvt. Ltd. Johnson & Johnson Astellas Pharma AstraZeneca CSL Emergent BioSolutions Royal (Wuxi) Bio-Pharmaceutical Co., Ltd. #Type Pneumococcal Conjugate Vaccine (PCV13) Pneumococcal Polysaccharide Vaccine (PPSV23) Other #Applications Pneumonia Meningitis Sepsis 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐁𝐮𝐲 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/dSwgtKsv #PneumoniaVaccine #Healthcare #Immunization #RespiratoryHealth #PublicHealth #VaccinationAwareness #PreventativeCare #MedicalInnovation #PediatricHealth #GlobalHealth

CDC Update: ACIP Recommended Adult Immunizations: Highlighting Pneumococcal The ACIP has published its updated recommendations for Adult Immunizations. Including in its recommendations, the newest adult pneumococcal vaccine covering 21 conjugates: Capvaxive. The ACIP recommends to vaccinate against pneumococcal with one of the following vaccines: - PCV 15 (Vaxneuvance) - Prevnar 20 - Capvaxive Access Vaccines strives to provide members the lowest prices on vaccines recommended by ACIP and supported by the CDC. Access Vaccines members receive discounted pricing on all brands of pneumococcal vaccines. Become an Access Vaccines member today and save on all your pneumococcal purchases. Click Here to Read the 2025 ACIP Adult Recommendations: https://lnkd.in/e_ZNsZ_E

CDC now only recommends COVID-19 double boosters for those over 65 years and younger patients with severe immuno-compromise. This CDC article that can be found at https://lnkd.in/gm6fdaHd includes some other interesting facts: The societal incremental cost-effectiveness ratio (ICER) for an additional dose of COVID-19 vaccine in persons aged ≥65 years was $356,534 per quality-adjusted life year saved for the base case estimate (18). Presumably for those <65 who are at even lower risk, the ICER must be in the orders of millions of dollars per QALY - hardly a cost-effective health strategy even in the richest of countries. During 2023–2024, ≥10% of COVID-19 vaccine recipients in V-safe reported health impact events during the 7 days after vaccination, such as being unable to complete daily activities (16). Hence, mRNA COVID-19 vaccines are highly reactogenic (2), far exceeding the reactogenicity of most if not all other routine licensed vaccines. During September 2023–August 2024, in persons without immunocompromise, VE (presumably against COVID-19–associated hospitalization but not stated) was 51% (95% CI = 45%–56%) 7–59 days after vaccination, waning to 15% (95% CI = 3%–26%) 120–179 days after vaccination (10). Hence, mRNA COVID-19 vaccines provided an average of 50% protection for approximately 2 months, far shorter protection than any other routine licensed vaccine. My take home message from this is 1. we need far better COVID-19 vaccines than the mRNA vaccines currently on offer, and 2. if COVID-19 mRNA vaccines had been put up for approval in anything other than the context of a pandemic, they would not have been granted a license based on the above data.

Understanding vaccine markets is a key input to increasing access to vaccines and a critical component to improving immunization coverage. The 2024 Global Vaccine Market Report provides a snapshot of vaccine markets globally in 2023, covering 88 vaccine products sold in 207 countries and procurement channels by 116 manufacturers. Some 𝗸𝗲𝘆 𝗼𝗯𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻𝘀 on the 2023 market: 1️⃣ 𝗚𝗹𝗼𝗯𝗮𝗹 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝘃𝗼𝗹𝘂𝗺𝗲𝘀 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗼 𝗽𝗿𝗲-𝗖𝗢𝗩𝗜𝗗; COVID-19 procurement ~1/6 of 2022 volumes (from ~7 to ~1bn doses) 2️⃣ 𝗚𝗹𝗼𝗯𝗮𝗹 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝘃𝗮𝗹𝘂𝗲 𝗴𝗿𝗲𝘄 𝗯𝘆 𝟭𝟱% 𝗼𝘃𝗲𝗿 𝘁𝗵𝗲 𝗽𝗮𝘀𝘁 𝟱 𝘆𝗲𝗮𝗿𝘀; driven by higher-price adult vaccines (COVID-19, PCV, shingles) and novel RSV vaccines and mAbs 3️⃣ 𝗥𝗲𝗺𝗮𝗶𝗻𝘀 𝗵𝗶𝗴𝗵𝗹𝘆 𝗰𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗲𝗱: 10 manufacturers captured ~70% of global volume; 10 manufacturers captured ~85% of financial value 4️⃣ 𝗚𝗲𝗼𝗴𝗿𝗮𝗽𝗵𝗶𝗰 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗽𝗮𝘁𝘁𝗲𝗿𝗻𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝘁𝗼 𝗽𝗿𝗲𝘃𝗶𝗼𝘂𝘀 𝘆𝗲𝗮𝗿𝘀, with the African Region and the Eastern Mediterranean Region producing <5% of the vaccines they procure 5️⃣ 𝗠𝗶𝗱𝗱𝗹𝗲 𝗜𝗻𝗰𝗼𝗺𝗲 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝘁𝗵𝗲 𝗱𝗿𝗶𝘃𝗲𝗿 𝗼𝗳 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝘃𝗼𝗹𝘂𝗺𝗲𝘀 (>50% of the total), 𝘄𝗵𝗶𝗹𝗲 𝗛𝗶𝗴𝗵 𝗜𝗻𝗰𝗼𝗺𝗲 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗱𝗿𝗶𝘃𝗲 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝘃𝗮𝗹𝘂𝗲 (>70% of total) 6️⃣ 𝗚𝗹𝗼𝗯𝗮𝗹𝗹𝘆, 𝗽𝗿𝗶𝗰𝗲𝘀 𝗮𝗿𝗲 𝘁𝗶𝗲𝗿𝗲𝗱 𝗯𝘆 𝗶𝗻𝗰𝗼𝗺𝗲 𝗴𝗿𝗼𝘂𝗽, with opportunity to streamline More details here: https://lnkd.in/eYTY8cqU

A recent study reveals promising results for the BNT162b2 XBB COVID-19 vaccine (Pfizer) in children aged 5 to 17 years. The updated vaccine showed 65% effectiveness in preventing hospitalizations and emergency department or urgent care visits for COVID-19-related acute respiratory infections. 🔑 Key Findings: 68% effectiveness in children aged 5–11 years. 63% effectiveness in adolescents aged 12–17 years. No hospitalizations were reported among vaccinated children. The study highlights the potential to avert thousands of hospitalizations and over 100,000 urgent care visits during respiratory virus seasons, underscoring the vaccine's role in reducing health care burdens and protecting pediatric populations. While limitations exist, these findings emphasize the need to prioritize vaccine uptake in children to mitigate severe outcomes and long-term consequences of COVID-19. How can we best address barriers to pediatric vaccination? Let’s discuss. #COVID19Vaccine #PediatricHealth #PublicHealth #Vaccination #HealthcareInnovation

🦠 Exciting findings from a recent study on the benefits and risks of COVID-19 vaccines have shed light on their crucial role in public health! The research quantitatively analyzes vaccine efficacy, revealing substantial protection against symptomatic COVID-19, severe illness, and hospitalization. While mild adverse effects were reported, serious complications were rare compared to the risks posed by the virus itself. The study emphasizes that the advantages of vaccination significantly outweigh the risks, particularly for high-risk groups. This comprehensive evaluation not only reinforces the importance of ongoing vaccination efforts but also aims to bolster public confidence in vaccine safety. 📈💉 #COVID19 #Vaccines #PublicHealth https://lnkd.in/d9cdKHd9

A Complete Guide of "Vaccines" [ PDF Guide ] ➡𝐂𝐥𝐢𝐜𝐤 𝐡𝐞𝐫𝐞 𝐟𝐨𝐫 𝐏𝐃𝐅 >> https://lnkd.in/dgD5mk-i #Vaccines_Market has witnessed significant growth over the past decade, driven by advancements in biotechnology and increased awareness of preventive healthcare. Vaccines play a crucial role in preventing infectious diseases and have become a cornerstone of public health initiatives worldwide. The market encompasses a wide range of vaccines, including those for influenza, hepatitis, human papillomavirus (HPV), and more recently, COVID-19. Factors such as government immunization programs, rising healthcare expenditure, and the growing prevalence of infectious diseases are key drivers propelling the growth of the vaccines market. Additionally, technological innovations and strategic collaborations among pharmaceutical companies are expected to further fuel market expansion. #Vaccines_Market is characterized by dynamic shifts influenced by various factors. One of the primary drivers is the increasing incidence of infectious diseases, which necessitates the development and distribution of effective vaccines. Government support through funding and immunization programs significantly boosts market growth. Moreover, advancements in biotechnology have led to the development of novel vaccines, such as mRNA vaccines, which have gained prominence during the COVID-19 pandemic. However, the market also faces challenges, including stringent regulatory requirements and high costs associated with vaccine development and production. Despite these hurdles, the market continues to evolve, with a focus on innovation and accessibility. ⏩ 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝 By Technology (excluding COVID 19 vaccines) By Technology (including COVID 19 vaccines) By Type By Disease Indication By Route of Administration By End-user By Region 𝑹𝒆𝒂𝒅 𝑵𝒆𝒘𝒔: https://lnkd.in/d9bKCJPG #Vaccines #Immunization #PublicHealth #VaccineResearch #DiseasePrevention #VaccinationPrograms #GlobalHealth #VaccineDevelopment #Immunotherapy #HealthcareInnovation #VaccineSafety #VaccineEfficacy #VaccineDistribution #InfectiousDiseases #VaccineTechnology #ChildhoodVaccination #ImmunizationAwareness #VaccineProduction #Healthcare #PreventiveMedicine #VaccinationCampaigns #VaccineIndustry #VaccineScience #PublicHealthInitiatives #ImmunizationPrograms

https://lnkd.in/dX8mFaiE Vaccines Beat UK COVID BOOSTER HEALTH-ECONOMICS - The base-case analysis results suggest that booster vaccination in the older adult and high-risk population offers significant benefits by averting symptomatic cases (701,549), deaths (5,599), outpatient cases (683,462), hospitalizations (18,086), and PCC cases (56,326), resulting in substantial direct medical cost (£112,174,054) and societal cost savings (£542,758,682). - The benefits observed in the base-case analysis increased as the vaccination strategies incorporated additional age groups, with the greatest benefits observed in the vaccination strategy targeting all individuals aged ≥30 years and the high-risk population aged 12–29 years, with 1,451,178 symptomatic cases, 5,913 deaths, 1,427,082 outpatient cases 24,096 hospitalizations, and 104,722 PCC cases prevented 48,929 QALYs gained, and cost savings of £174,992,231 in medical costs and £1,212,143,704 in societal costs.